TFS HealthScience Elevates Miriam Martin to Key Leadership Role
Miriam Martin steps into VP role at TFS HealthScience, driving growth and innovation in clinical development.


LUND, Sweden – March 25, 2025 – TFS HealthScience has named Miriam Martin as its new Vice President of Business Development, Clinical Development Services (CDS), marking a significant milestone in her 15-year journey with the company. A dedicated leader with deep industry expertise, Miriam has played a pivotal role in shaping TFS’s commercial success and global expansion. From navigating key acquisitions to enhancing the company’s Functional Service Provider (FSP) model, she has been instrumental in building flexible, high-quality strategic resourcing solutions that align with the evolving needs of partners. Now joining the TFS Executive Committee, she will spearhead efforts to strengthen client engagement, accelerate business growth, and drive clinical development innovation.
Miriam’s appointment comes amid rapid advancements in TFS’s core therapeutic areas, including oncology, ophthalmology, dermatology, and neuroscience. With new clinical programs targeting diabetic macular edema, pancreatic cancer, multiple sclerosis, and complex wound healing, TFS continues to expand its scientific impact. Reflecting on her new role, Miriam expressed gratitude for the trust and investment TFS has placed in her and emphasized her commitment to fostering strong partnerships and advancing patient-centered solutions. With her leadership, the company is poised for continued momentum, reinforcing its reputation as a global leader in strategic clinical research.

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix

Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park

Discussion